Conferences Cardiologists share their perspective on The Medicines Co.'s inclisiran and other key events from AHA's 2019 Scientific Sessions Following AHA 2019 Scientific Sessions, Novartis announced its intention to buy The Medicines Company for nearly $10B, based on promising results on its small interfering RNA (siRNA) therapy, inclisiran. The therapy targets PCSK9
